OptiBiotix Health PLC Launch of extended range of products at Vitafoods (2069N)
May 08 2018 - 2:00AM
UK Regulatory
TIDMOPTI
RNS Number : 2069N
OptiBiotix Health PLC
08 May 2018
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Launch of extended range of LP(LDL) (R) and SlimBiome(R)
products at Vitafoods 2018
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, and
diabetes announces that it will be presenting an extended range of
products and presenting new research data on its LP(LDL) (R) and
SlimBiome(R) products at the Vitafoods European tradeshow in Geneva
from the 15-17 May 2018. The event provides the opportunity to
connect with 16,500 industry decision makers from the supplements,
nutraceutical, functional food and beverage industries and is
viewed as one of the world's leading trade fairs for the food and
drinks industry.
LP-LDL(R)
OptiBiotix will be showcasing its LP(LDL) (R) probiotic for the
reduction of high cholesterol and high blood pressure in a number
of new product concepts with its global manufacturing partner Sacco
S.r.l. In addition to an exhibitor presence, the Company will be
presenting further results of its human studies in an abstract and
poster titled "Lactobacillus plantarum LP(LDL) (R) reduces
cholesterol in adults with normal to mildly elevated cholesterol.
".
LP(LDL) (R) has gone through a successful commercial development
since its launch at VitaFoods in May 2017 announcing seven
manufacturing, application and distribution commercial agreements.
The unique ability of LP(LDL) (R) to reduce both high cholesterol
and high blood pressure has attracted a lot of media and industry
attention leading to LP(LDL) (R) being shortlisted as 'Probiotic
Product of the Year' at the show.
SlimBiome(R)
OptiBiotix will be showcasing its award winning SlimBiome(R)
presented in a range of new product concepts which include natural
fruit gummies, muesli pots, Nutri-Bites(R) and flavours for new
bars. In addition to an exhibitor presence, the Company will be
presenting results of its humans studies on SlimBiome(R) carried
out by Oxford Brookes University. The study will be presented as an
abstract and poster titled "SlimBiome reduces hunger and food
cravings in healthy overweight and obese adults". The study shows
that if you compare control and test groups who take SlimBiome(R)
or a placebo the SlimBiome(R) group:-
-- Feel fuller and are less hungry
-- Have less food cravings
-- Change their food choice so eat less sweet or fatty foods
Following on from winning the award for 'Best Functional
Ingredient for Health and Well Being' at Food Matters in November
2017, SlimBiome(R) has been shortlisted for the award of
'Ingredient of the Year: Weight Management'.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are extremely
pleased to be attending Vitafoods with a range of new products, new
human studies on SlimBiome(R) and a growing list of industry
partners. We are confident that our participation at VitaFoods will
help progress existing discussions with corporate partners and open
up opportunities in new territories for the manufacture and
distribution of our growing range of products. Having both
SlimBiome(R) and LP(LDL) (R) nominated for such prestigious
industry awards will help attract commercial interest in our
technology and products. Finally, we are really excited by the
results of the human study on SlimBiome(R) which supports our
scientific understanding of its mechanism of action, independent
consumer surveys and all the success stories we receive from
customers who use our GoFigure(R) products containing SlimBiome(R)
to help manage their weight. Having a product with scientific data,
which shows it helps to reduce hunger and snacking and most
importantly changes a users food choice so they eat less sweet and
fatty foods, is really exicting. Hunger free dieting is now a
consumer option and we hope that our wider range of products
containing this unique formulation will help bring the benefits of
SlimBiome(R) technology to a wider international audience."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213
0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Abigail Wayne (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESBDGDUSSGBGIS
(END) Dow Jones Newswires
May 08, 2018 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024